Sero-surveillance for surra in cattle using native surface glycoprotein antigen from Trypanosoma evansi

2013 ◽  
Vol 196 (3-4) ◽  
pp. 258-264 ◽  
Author(s):  
Krishnendu Kundu ◽  
Anup Kumar Tewari ◽  
Samarchith P. Kurup ◽  
Surajit Baidya ◽  
Jammi Raghavendra Rao ◽  
...  
Keyword(s):  
Trypanosoma Evansi ◽  
Surface Glycoprotein ◽  
Glycoprotein Antigen ◽  
Native Surface

scholarly journals Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells.

1987 ◽  
Vol 105 (2) ◽  
pp. 983-990 ◽  
Author(s):  
S Jalkanen ◽  
R F Bargatze ◽  
J de los Toyos ◽  
E C Butcher
Keyword(s):  
Monoclonal Antibody ◽  
Lymph Node ◽  
Human Lymphocyte ◽  
Molecular Mechanisms ◽  
Polyclonal Antiserum ◽  
Surface Glycoprotein ◽  
Lymphoid Tissues ◽  
Specific Cell ◽  
High Endothelial Venules ◽  
Glycoprotein Antigen

The tissue-specific homing of lymphocytes is directed by specialized high endothelial venules (HEV). At least three functionally independent lymphocyte/HEV recognition systems exist, controlling the extravasation of circulating lymphocytes into peripheral lymph nodes, mucosal lymphoid tissues (Peyer's patches or appendix), and the synovium of inflamed joints. We report here that antibodies capable of inhibiting human lymphocyte binding to one or more HEV types recognize a common 85-95-kD lymphocyte surface glycoprotein antigen, defined by the non-blocking monoclonal antibody, Hermes-1. We demonstrate that MEL-14, a monoclonal antibody against putative lymph node "homing receptors" in the mouse, functionally inhibits human lymphocyte binding to lymph node HEV but not to mucosal or synovial HEV, and cross-reacts with the 85-95-kD Hermes-1 antigen. Furthermore, we show that Hermes-3, a novel antibody produced by immunization with Hermes-1 antigen isolated from a mucosal HEV-specific cell line, selectively blocks lymphocyte binding to mucosal HEV. Such tissue specificity of inhibition suggests that MEL-14 and Hermes-3 block the function of specific lymphocyte recognition elements for lymph node and mucosal HEV, respectively. Recognition of synovial HEV also involves the 85-95-kD Hermes-1 antigen, in that a polyclonal antiserum produced against the isolated antigen blocks all three classes of lymphocyte-HEV interaction. From these studies, it is likely that the Hermes-1-defined 85-95-kD glycoprotein class either comprises a family of related but functionally independent receptors for HEV, or associates both physically and functionally with such receptors. The findings imply that related molecular mechanisms are involved in several functionally independent cell-cell recognition events that direct lymphocyte traffic.

Serological and molecular survey of Trypanosoma evansi in Camels (Camelus dromedarius) in Maiduguri, North-east, Nigeria

2021 ◽  
Vol 42 (1) ◽  
pp. 56-62
Author(s):  
S.A. Mamman ◽  
G. Abongaby ◽  
O. Salami ◽  
J.P. Yidawi ◽  
D.A. Dakul
Keyword(s):  
Diagnostic Techniques ◽  
Trypanosoma Evansi ◽  
Surface Glycoprotein ◽  
Dromedary Camel ◽  
Serological Method ◽  
Cross Sectional ◽  
North East ◽  
Variable Surface ◽  
Pcr Targeting ◽  
Pcr Techniques

To date, camels still remain an important work animal as well as source of protein to humans in the Sudan and Sahel regions of Nigeria. Therefore, a cross-sectional study was conducted on 150 camels slaughtered in Maiduguri central abattoir to determine the prevalence of Trypanosoma evansi using Card Agglutination Test (CATT) and Polymerase Chain Reaction (PCR) techniques. Overall, 30 (20%) of the camels tested were seropositive while PCR targeting the 227 base pair of the Variable Surface Glycoprotein (VSG) gene of T. evansi detected the DNA of the parasite in 9 out of the 30seropositive camels. Higher infection was found among adult compared to the young camels using the two diagnostic techniques; 24.1% vs 19.0% and 10.3% vs 4.6%, for CATT and PCR techniques, respectively. However, the differences being not statistically significant (P > 0.05) for the two methods of diagnosis. Furthermore, significantly (P < 0.05)higher prevalence of infection was recorded among male compared to female camels using the serological method of diagnosis, while (P > 0.05) using the molecular method; 27.5% vs 13.6% for CATT and 10.1% vs 2.5% for PCR. Camels with PCV =24 %( mean: 19.8923 ± 4.0931) recorded significantly (P < 0.05) higher prevalence of 23.1% than those with PCV = 25% (mean 31.7294 ± 5.50584), where the prevalence was 17.6%.The results of this study showed that camel trypanosomosis is endemic in the study area.  Furtherstudiesto elucidate the epidemiology and socioeconomic impact of this disease in the northeast region of Nigeria are desirable. Keywords:Serology, PCR, Dromedary camel, T.evansi, Maiduguri

Characterization of an Anti-Ebola virus Hyperimmune Globulin Derived from Convalescent Plasma

2021 ◽  
Author(s):  
Jonathan M Ciencewicki ◽  
Andrew S Herbert ◽  
Nadia Storm ◽  
Nicole M Josleyn ◽  
Kathleen Huie ◽  
...  
Keyword(s):  
Ebola Virus ◽  
Virus Disease ◽  
Fold Increase ◽  
Surface Glycoprotein ◽  
Post Exposure Prophylaxis ◽  
Emerging Viruses ◽  
Live Virus ◽  
Glycoprotein Antigen ◽  
Ebov Infection ◽  
Exposure Prophylaxis

Abstract Backrgound Convalescent plasma has been used to treat many viral diseases including Ebola. The manufacture of a purified anti-Ebola virus (EBOV) intravenous immunoglobulin (IVIG) from pooled convalescent plasma is described in this paper. Methods An ELISA targeting an EBOV surface glycoprotein antigen was used to determine the immunoglobulin titer of pooled plasma and purified anti-EBOV IVIG. Anti-EBOV IVIG was also tested in neutralization assays using a vesicular stomatitis virus pseudovirion expressing EBOV glycoprotein on its surface and with live EBOV. Finally, the efficacy of the anti-EBOV IVIG was assessed in a mouse model of EBOV infection. Results In the ELISA, the anti-EBOV IVIG was shown to have a seven-fold increase in IgG titer over pooled convalescent plasma. In both the pseudovirion and live virus assays, the anti-EBOV IVIG showed approximately five- to six-fold increased potency over pooled plasma. Anti-EBOV IVIG also significantly improved survivability in mice infected with the virus when administered concurrently or two days after infection. Conclusions These data support this purified anti-EBOV IVIG merits additional investigation and clinical trials for treatment and post-exposure prophylaxis of Ebola virus disease. The experience gained can be applied to manufacture hyperimmune globulins against other emerging viruses.

scholarly journals Towards a New Reference Test for Surra in Camels

2009 ◽  
Vol 16 (7) ◽  
pp. 999-1002 ◽  
Author(s):  
Thao Tran ◽  
Filip Claes ◽  
Didier Verloo ◽  
Henri De Greve ◽  
Philippe Büscher
Keyword(s):  
Antigenic Variation ◽  
Trypanosoma Evansi ◽  
Surface Glycoprotein ◽  
Antibody Detection ◽  
Enzyme Linked Immunosorbent Assay ◽  
Reference Test ◽  
Perfect Agreement ◽  
Cutoff Value ◽  
Variable Surface ◽  
Variable Antigen

ABSTRACT Current serological diagnosis of Trypanosoma evansi infection in camels is based on the native variable antigen type RoTat 1.2. The goal of this study was to develop a novel serological diagnostic test based on a nonvariable protein and freed from the use of rats or mice for its production. An enzyme-linked immunosorbent assay using a recombinant extracellular domain of invariant surface glycoprotein 75 (ELISA/rISG75) was developed and tested on a collection of 184 camel sera. The results were compared to those obtained from three established antibody detection tests based on variable surface glycoprotein RoTat 1.2: an ELISA for T. evansi (ELISA/T. evansi), a card agglutination test for trypanosomiasis (CATT/T. evansi), and an immune trypanolysis (TL) assay. The ELISA/rISG75 and the ELISA/T. evansi showed a sensitivity of 94.6% (95% confidence interval [CI], 87.8 to 98.2%, at 19% positivity cutoff value) and 98.9% (95% CI, 94.1 to 99.8, at 12% positivity cutoff value), respectively. The ELISA/rISG75 had 100% specificity (CI, 95.9 to 100%), while the ELISA/T. evansi showed 98.9% specificity (CI, 95.9 to 100%). The ELISA/rISG75 demonstrated an almost perfect agreement with the TL assay, the CATT/T. evansi, and the ELISA/T. evansi, with kappa scores of at least 0.94. The ELISA/rISG75, having a performance comparable to that of the gold standard (the TL assay) and being independent of antigenic variation, may become a new reference test for surra in camels. It opens avenues for the diagnosis of T. evansi infections in other hosts as well as for the development of a pan-Trypanozoon test for detection of Trypanosoma brucei brucei, T. b. gambiense, T. b. rhodesiense, T. evansi, and T. equiperdum.

Differential expression of murine macrophage surface glycoprotein antigens in intracellular membranes

1987 ◽  
Vol 87 (1) ◽  
pp. 113-119
Author(s):  
M.J. Smith ◽  
G.L. Koch
Keyword(s):  
Differential Expression ◽  
Surface Glycoprotein ◽  
Murine Macrophage ◽  
Intracellular Pool ◽  
Intracellular Membranes ◽  
Immunofluorescence Studies ◽  
Glycoprotein Antigen ◽  
Tumour Cell Lines ◽  
Punctate Pattern

A monoclonal antibody recognizing a novel murine macrophage glycoprotein antigen (MAG) was prepared by the hybridoma technique. Using live and permeabilized macrophages to estimate surface and total MAG, respectively, it was found that at least 50% of the total antigen was intracellular. In contrast, another macrophage surface glycoprotein antigen, Mac-1, was undetectable in the intracellular pool. Immunofluorescence studies confirmed the existence of a substantial intracellular pool of MAG antigen. Similar results were obtained with a panel of cultured tumour cell lines. In one such cell line, it was shown that surface MAG existed in a distinct punctate pattern indicative of microdomains, whereas surface Mac-1 antigen gave a uniform distribution. The possible role of the surface microdomains in the differential expression of the two surface glycoproteins in intracellular membranes is discussed.

Expressed truncated N-terminal variable surface glycoprotein (VSG) of Trypanosoma evansi in E. coli exhibits immuno-reactivity

2012 ◽  
Vol 187 (1-2) ◽  
pp. 1-8 ◽  
Author(s):  
P.P. Sengupta ◽  
M. Balumahendiran ◽  
V. Balamurugan ◽  
G.R. Rudramurthy ◽  
K. Prabhudas
Keyword(s):  
Trypanosoma Evansi ◽  
Surface Glycoprotein ◽  
E Coli ◽  
Variable Surface Glycoprotein ◽  
Variable Surface
Sign in / Sign up

Export Citation Format

Share Document